InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,952.00
(
-0.19%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.58
(
0.04%
)
Bitcoin
57,749.94
(
-0.84%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 132484

Tuesday, 12/17/2013 7:45:24 PM

Tuesday, December 17, 2013 7:45:24 PM

Post# of 251670
BIIB/Samsung* will develop anti-TNF FoB’s in Europe:

http://finance.yahoo.com/news/biogen-idec-samsung-bioepis-announce-070000638.html

Although this PR doesn’t specify which anti-TNF FoB’s are under development, clinicaltrials.gov shows trials in progress for Remicade and Enbrel biosimilars.

See #msg-74411298 for information about pricing of these products.

Curiously, MRK is not mentioned in this PR even though it joined up with Samsung Bioepis in Feb 2013 (#msg-84781042).

*d/b/a Samsung Bioepis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up